CR9678A - 7- aza-indazoles sustituidos , composiciones que los contienen, procedimiento de fabricacion y utilizacion - Google Patents

7- aza-indazoles sustituidos , composiciones que los contienen, procedimiento de fabricacion y utilizacion

Info

Publication number
CR9678A
CR9678A CR9678A CR9678A CR9678A CR 9678 A CR9678 A CR 9678A CR 9678 A CR9678 A CR 9678A CR 9678 A CR9678 A CR 9678A CR 9678 A CR9678 A CR 9678A
Authority
CR
Costa Rica
Prior art keywords
compositions
indazols
contain
manufacturing
use procedure
Prior art date
Application number
CR9678A
Other languages
English (en)
Inventor
Bjergarde Kristen
Nair Anil
Patek Marcel
Dodson Mark
Ackerman-Berrier Martha
Smrcina Martin
Leroy Vincent
Bacque Eric
Tabart Michel
Ronan Baptiste
Viviani Fabrice
Souaille Catherine
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CR9678A publication Critical patent/CR9678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a nuevos 7-azaindazoles de formula (I) especificos que presentan una actividad moduladora de la actividad de proteinas, en particular de quinasas, a las composiciones que los contienen y su utilizacion como medicamento, particularmente como agentes anticancerigenos.
CR9678A 2005-08-04 2008-01-22 7- aza-indazoles sustituidos , composiciones que los contienen, procedimiento de fabricacion y utilizacion CR9678A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508316A FR2889526B1 (fr) 2005-08-04 2005-08-04 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
CR9678A true CR9678A (es) 2008-09-22

Family

ID=36177926

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9678A CR9678A (es) 2005-08-04 2008-01-22 7- aza-indazoles sustituidos , composiciones que los contienen, procedimiento de fabricacion y utilizacion

Country Status (29)

Country Link
US (1) US8058290B2 (es)
EP (1) EP1912988B1 (es)
JP (1) JP5128475B2 (es)
KR (1) KR101263970B1 (es)
CN (2) CN102093353B (es)
AR (1) AR057719A1 (es)
AU (1) AU2006277855B2 (es)
BR (1) BRPI0614304A2 (es)
CA (1) CA2617293C (es)
CR (1) CR9678A (es)
DO (1) DOP2006000179A (es)
EA (1) EA019302B1 (es)
EC (1) ECSP088152A (es)
FR (1) FR2889526B1 (es)
HN (1) HN2008000188A (es)
IL (1) IL188792A0 (es)
MA (1) MA29652B1 (es)
MX (1) MX2008001614A (es)
MY (1) MY147488A (es)
NI (1) NI200800020A (es)
NO (1) NO20081013L (es)
NZ (1) NZ565396A (es)
PE (1) PE20070240A1 (es)
TN (1) TNSN08024A1 (es)
TW (1) TWI378930B (es)
UA (1) UA94417C2 (es)
UY (1) UY29727A1 (es)
WO (1) WO2007017577A1 (es)
ZA (1) ZA200800965B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2010033966A1 (en) * 2008-09-22 2010-03-25 The Government of the United State of America, as represented by the Secretary of the Navy Tether-containing conducting polymers
US8931114B2 (en) 2008-09-22 2015-01-13 The United States Of America, As Represented By The Secretary Of The Navy Elastomeric composites with tether-containing, conducting polymers for nanoscale diffusion control
WO2010125799A1 (ja) * 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
EP2470533A4 (en) 2009-08-24 2013-01-23 Ascepion Pharmaceuticals Inc UREA COMPOUNDS CONTAINING A 5,6-BICYCLIC HETEROARYL GROUP
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
ES2528269T3 (es) * 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
WO2013045413A1 (en) * 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
EP3057962B1 (en) 2013-10-16 2023-10-18 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
US11059817B2 (en) 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
HRP20211006T1 (hr) 2016-09-23 2021-09-17 Novartis Ag Spojevi indazola za uporabu kod ozljeda tetiva i/ili ligamenata
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
AU2017373758B2 (en) * 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN111138426B (zh) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 吲唑类激酶抑制剂及其用途
CN109456280B (zh) * 2018-12-24 2020-11-10 锦州医科大学 含有脲结构的4-苯基噻唑-2-胺类衍生物及其制备方法与应用
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
CN118561776A (zh) * 2024-05-15 2024-08-30 沈阳药科大学 一种n-(3-氟苄基)-1h-吲唑-5-胺衍生物及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1302287A (es) * 1970-07-21 1973-01-04
DE2538950A1 (de) * 1975-09-02 1977-03-03 Basf Ag Verfahren zur herstellung von 2,6- dichlor-nicotinsaeuren
DE2701610A1 (de) * 1977-01-17 1978-07-20 Basf Ag Farbstoffzubereitungen fuer cellulose und cellulosehaltiges textilmaterial und neue farbstoffe
DD154538A1 (de) * 1979-07-30 1982-03-31 Eberhard Schroetter Verfahren zur herstellung substituierter 2,4-und 2,6-dihalogen-pyridine
JPH04117362A (ja) * 1990-09-07 1992-04-17 Idemitsu Kosan Co Ltd ピリジン誘導体およびその塩ならびに該物質を有効成分とする殺虫・殺ダニ剤
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
JP4555547B2 (ja) 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
US6977262B2 (en) * 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
FR2827603B1 (fr) * 2001-07-18 2003-10-17 Oreal Composes derives de diaminopyrazole substitues par un radical heteroaromatique et leur utilisation en teinture d'oxydation des fibres keratiniques
WO2003027094A2 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
AU2003254051A1 (en) 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
MXPA05001688A (es) * 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
NZ541836A (en) 2003-02-27 2008-12-24 Palau Pharma Sa Pyrazolopyridine derivatives
CN1809351A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005027095A1 (ja) 2003-09-16 2005-03-24 Matsushita Electric Industrial Co., Ltd. 符号化装置および復号化装置
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
ES2545382T3 (es) 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
BRPI0619672A2 (pt) 2005-11-09 2011-10-11 Memory Pharm Corp composto, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
AU2006277855B2 (en) 2012-08-23
PE20070240A1 (es) 2007-04-12
JP2009503037A (ja) 2009-01-29
NO20081013L (no) 2008-04-14
MY147488A (en) 2012-12-14
TW200745103A (en) 2007-12-16
CN101304998A (zh) 2008-11-12
EA019302B1 (ru) 2014-02-28
ZA200800965B (en) 2009-11-25
US8058290B2 (en) 2011-11-15
ECSP088152A (es) 2008-02-20
TNSN08024A1 (en) 2009-07-14
KR20080031939A (ko) 2008-04-11
US20080182844A1 (en) 2008-07-31
IL188792A0 (en) 2008-08-07
FR2889526B1 (fr) 2012-02-17
UA94417C2 (ru) 2011-05-10
CA2617293A1 (fr) 2007-02-15
CN101304998B (zh) 2012-09-05
DOP2006000179A (es) 2007-03-31
NI200800020A (es) 2011-01-10
AU2006277855A1 (en) 2007-02-15
MX2008001614A (es) 2008-04-04
CN102093353A (zh) 2011-06-15
EA200800514A1 (ru) 2008-06-30
EP1912988B1 (fr) 2014-04-16
UY29727A1 (es) 2007-02-28
AR057719A1 (es) 2007-12-12
CN102093353B (zh) 2013-06-12
HN2008000188A (es) 2010-11-09
FR2889526A1 (fr) 2007-02-09
CA2617293C (fr) 2015-09-22
WO2007017577A1 (fr) 2007-02-15
EP1912988A1 (fr) 2008-04-23
KR101263970B1 (ko) 2013-05-13
TWI378930B (en) 2012-12-11
BRPI0614304A2 (pt) 2011-03-22
JP5128475B2 (ja) 2013-01-23
HK1125928A1 (en) 2009-08-21
NZ565396A (en) 2011-03-31
MA29652B1 (fr) 2008-07-01

Similar Documents

Publication Publication Date Title
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
SV2011003855A (es) Heteroarilos sustituidos
MX2010006436A (es) Derivados peptidos mimeticos de eritropoyetina y sus sales farmaceuticas, su preparacion y usos.
UY30276A1 (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapéutica
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY29486A1 (es) Compuestos utiles en terapia
CR10749A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CR9231A (es) Pirroles sustituidos, composiciones que los contienen, procesos de fabricacion y utilizacion
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CR9115A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CR10390A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparacion, composiciones que las contienen y utilizacion
CR10382A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
DOP2005000246A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CR10428A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion
GT200700016A (es) 7-aza-indazoles sustituidos; composiciones que les contienen; procedimiento de fabricación y utilización.
CR7320A (es) Tiofen. y tiazolsulfonamidas como agentes antineoplasicos